Experimental combo targets Hard-to-Treat brain tumors
NCT ID NCT04826393
First seen Nov 01, 2025 · Last updated May 12, 2026 · Updated 25 times
Summary
This early-phase study tested two drugs, ASP8374 and cemiplimab, in 14 people with recurrent glioblastoma, an aggressive brain cancer. The goal was to find a safe dose and see if giving the drugs before surgery could increase cancer-fighting immune cells in the tumor. While not a cure, the approach aims to better control the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Brigham and Women's Hospital
Boston, Massachusetts, 02115, United States
-
Columbia University Medical Center
New York, New York, 10032, United States
-
Hospital of the University of Pennsylvania, Abramson Cancer Center
Philadelphia, Pennsylvania, 19104, United States
-
University of Cincinnati Medical Center
Cincinnati, Ohio, 45219, United States
Conditions
Explore the condition pages connected to this study.